Your Visual Guide Brain Metastases

Understand this diagnosis through data, infographics, and evidence based on modern classification and current research.

~200,000
New Brain Metastases Cases per Year (U.S.)
Understanding Brain Metastases
What Are Brain Metastases & How Are They Classified?
Brain metastases are the most common intracranial tumors in adults, occurring in 10–30% of cancer patients. Treatment is guided by the primary cancer type, molecular drivers (EGFR, ALK, HER2, BRAF), and number of lesions.
Brain Metastasis
Primary Cancer Type?
Lung Cancer
Lung Cancer (~40-50%)
Most common cause
NSCLC (EGFR, ALK) SCLC
Breast Cancer
Breast Cancer (~15-25%)
HER2+ and TNBC highest risk
HER2-positive Triple-negative
Melanoma
Melanoma (~5-20%)
High CNS tropism, immunotherapy responsive
BRAF V600E NRAS Wild-type
Other
Other (~10-20%)
Renal, colorectal, others
Renal cell Colorectal Unknown primary
Tumor Grading
Brain Metastases by Primary Cancer
Brain metastases are classified by the primary cancer type, which determines molecular targets and treatment options.
1
Non-Small Cell Lung Cancer
Most common cause of brain metastases. EGFR, ALK, ROS1, and KRAS mutations guide targeted therapy selection. CNS-penetrant TKIs available.
2
Small Cell Lung Cancer
High rate of brain metastases (~50%). Prophylactic cranial irradiation (PCI) reduces incidence. Immunotherapy increasingly used.
3
Breast Cancer
HER2+ and triple-negative subtypes have highest brain tropism. Tucatinib+trastuzumab for HER2+. Limited CNS options for TNBC.
4
Melanoma
High brain metastasis rate (~40-50%). Dramatic responses to combination immunotherapy (nivo+ipi). BRAF-targeted therapy for BRAF-mutant.
5
Renal Cell Carcinoma
Brain metastases in 5-10%. Respond to SRS. Immunotherapy (nivolumab/cabozantinib) has CNS activity.
6
Colorectal Cancer
Brain metastases are relatively rare (~3%). Often late in disease course. Limited systemic treatment options for CNS disease.
7
Leptomeningeal Disease
Carcinomatous meningitis with cancer cells in CSF. Diagnosed by MRI and CSF cytology. Poor prognosis, intrathecal therapy.
Molecular Markers
The Key Biomarkers
Modern classification depends on specific molecular markers. Each reveals something different about the tumor.
Predictive
EGFR
Epidermal Growth Factor Receptor
Mutations (exon 19 del, L858R) predict response to osimertinib, which has excellent CNS penetration and activity.
NSCLC
Predictive
ALK
Anaplastic Lymphoma Kinase
Rearrangements predict response to lorlatinib (3rd-gen ALK TKI) with superior CNS penetration and activity.
NSCLC
Predictive
HER2
Human Epidermal Growth Factor Receptor 2
Overexpression predicts response to tucatinib+trastuzumab+capecitabine with significant CNS activity.
Breast cancer
Predictive
BRAF V600E
BRAF Kinase Mutation
Present in ~50% of melanoma. Dabrafenib+trametinib combination has intracranial response rates of 50-60%.
Melanoma
Predictive
PD-L1
Programmed Death-Ligand 1
Expression predicts response to checkpoint immunotherapy. Combination nivo+ipi has >50% intracranial response in melanoma.
Multiple cancers
Predictive
KRAS G12C
KRAS Mutation
Sotorasib and adagrasib have CNS activity in KRAS G12C-mutant NSCLC brain metastases.
NSCLC
Predictive
ROS1
ROS1 Rearrangement
Predicts response to entrectinib and lorlatinib, both with CNS penetration for brain metastases.
NSCLC
Predictive
NTRK
Neurotrophic Receptor Tyrosine Kinase
Fusions across tumor types. Larotrectinib and entrectinib show intracranial activity.
Tumor-agnostic
Signs & Symptoms
Brain Metastases Signs & Symptoms
Symptoms depend on metastasis number, location, and size. Some patients are asymptomatic at diagnosis.

Headache

New or worsening headache, often worse in the morning. Present in ~50% of patients. May indicate raised intracranial pressure.

Focal Neurological Deficits

Weakness, numbness, or speech difficulties depending on metastasis location. Often gradual onset.

Seizures

New-onset seizures in a cancer patient should prompt brain imaging. Present in ~20% of brain metastases.

Cognitive Changes

Memory loss, confusion, personality changes, especially with multiple or frontal metastases.

Visual Changes

Visual field defects, double vision, or blurred vision depending on location and mass effect.

Leptomeningeal Signs

Cranial neuropathies, radiculopathy, headache, and altered mental status from meningeal involvement.

Diagnosis
The Diagnostic Journey
From first brain MRI to molecular profiling of the primary cancer — guiding treatment decisions.
1

Brain MRI

Contrast-enhanced MRI is the gold standard. Identifies number, size, and location of metastases

2

Staging CT/PET

Whole-body staging to assess systemic disease burden and primary cancer status

3

Molecular Profiling

Tissue or liquid biopsy for actionable mutations (EGFR, ALK, HER2, BRAF, PD-L1)

4

GPA Scoring

Graded Prognostic Assessment based on primary cancer, age, KPS, number of metastases

5

Neurosurgical Consult

For large, symptomatic, or solitary metastases amenable to surgical resection

6

Treatment Plan

Multidisciplinary: local (SRS/surgery) vs systemic (immunotherapy/targeted) vs combination

Treatment
Treatment Options for Brain Metastases
Modern treatment is personalized based on primary cancer type, molecular profile, number of metastases, and systemic disease status.

Stereotactic Radiosurgery

Standard for limited brain metastases (1-10). Single-fraction, high-dose radiation to each lesion. Excellent local control ~85-90%.

Surgery

For large (>3cm), symptomatic, or solitary metastases causing mass effect. Post-operative SRS to resection cavity.

Whole Brain Radiation

For multiple (>10) metastases or leptomeningeal disease. Hippocampal-avoidance WBRT reduces cognitive toxicity.

Immunotherapy

Checkpoint inhibitors (nivolumab, ipilimumab, pembrolizumab) have significant intracranial activity, especially in melanoma.

Targeted Therapy

CNS-penetrant agents: osimertinib (EGFR), lorlatinib (ALK), tucatinib (HER2), dabrafenib+trametinib (BRAF).

Clinical Trials

SRS+immunotherapy combinations, novel CNS-penetrant agents, and liquid biopsy-guided approaches under investigation.

Find matching trials →
Care Team
Your Multidisciplinary Care Team
Brain metastases management requires close collaboration between the primary oncologist, neurosurgery, and radiation oncology.
Core Specialists

Neurosurgeon

Primary specialist for surgical resection and skull base approaches

Radiation Oncologist

Plans and delivers radiation therapy and stereotactic radiosurgery

Neuro-oncologist

For higher-grade or refractory brain metastases requiring systemic therapy

Support Team

Neuroradiologist

Specialized imaging interpretation and monitoring

Neuropathologist

Tissue analysis, WHO grading, and molecular profiling

Nurse Navigator

Guides you through appointments, insurance, and logistics

Resources
Support Organizations
Organizations providing information, community, and support for brain metastases patients and caregivers.

Metavivor

The sole US nonprofit dedicated to awareness and research for metastatic breast cancer including brain metastases.

Visit Metavivor →

LUNGevity Foundation

Largest national lung cancer nonprofit funding research and supporting patients with brain metastases.

Visit LUNGevity Foundation →

Melanoma Research Foundation

Dedicated to melanoma research, education, and support, including brain metastasis management.

Visit Melanoma Research Foundation →

National Brain Tumor Society

Leading nonprofit investing in research, advocacy, and patient services for all brain tumors.

Visit National Brain Tumor Society →

Want to Explore Clinical Trials?

Search clinical trials for brain metastases and find the ones that match your primary cancer type and molecular profile.

Find Clinical Trials →